SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NeuroMetrix, Inc. (NURO) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 42/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NURO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.97
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.96
Book Value / Share$0.00
Revenue / Share$1.54
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-181.60 |
$7.3M |
$-9.19M |
-125.9% |
| 2016 |
$-178.20 |
$12.03M |
$-14.91M |
-124% |
| 2017 |
$-75.58 |
$17.09M |
$-12.86M |
-75.2% |
| 2018 |
$0.02 |
$16.09M |
$23.61K |
0.1% |
| 2019 |
$-30.15 |
$9.27M |
$-3.65M |
-39.4% |
| 2020 |
$-0.53 |
$7.38M |
$-2M |
-27.1% |
| 2021 |
$-0.86 |
$8.25M |
$-2.21M |
-26.7% |
| 2022 |
$-4.90 |
$8.26M |
$-4.37M |
-52.9% |
| 2023 |
$-6.27 |
$5.9M |
$-6.53M |
-110.6% |
| 2024 |
$-3.96 |
$3.03M |
$-7.81M |
-257.4% |
